Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05038449
Other study ID # KPC/QSXJ/01
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date September 6, 2021
Est. completion date September 1, 2023

Study information

Verified date September 2021
Source Shanghai Public Health Clinical Center
Contact Hongzhou Lu, Ph.D
Phone +86-021-37990333
Email luhongzhou@fudan.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed for single-center, randomized, open label, standard therapy controlled. 60 COVID-19 subjects with a treatment period of 10 days and follow-up until 28 days after enrollment.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date September 1, 2023
Est. primary completion date June 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. At the time of signing ICF, the subjects were 18 to 65 years old (including 18 and 65 years old), both men and women; 2. Within 72 hours before screening, any samples confirmed by the laboratory were positive for SARS-CoV-2; 3. Clinical classification was ordinary type according to the Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial 8th Edition); 4. Symptoms appeared = 5 days before randomization; Such as fever, cough, shortness of breath, sore throat and diarrhea; 5. Subjects were able to communicate well with the investigator, and understand and comply with the requirements of this study, understand and sign the ICF. Exclusion Criteria: 1. Severe type patients who comply with any of the following: - Shortness of breath, RR = 30 times/min; - In the resting state, the oxygen saturation is less than or equal to 93%; - Arterial oxygen partial pressure (PaO2)/oxygen inhalation concentration (FiO2) = 300 mmHg (1mmHg=0.133kPa). Note: At high altitudes (above 1000 m), PaO2/FiO2 shall be corrected according to the following formula: PaO2/FiO2 × [760/atmospheric pressure (mmHg)]; - Pulmonary imaging shows that patients with obvious lesion progression > 50% within 24-48 hours. 2. Critical type patients who comply with any of the following: - Respiratory failure occurs and mechanical ventilation is required; - Shock; - ICU monitoring and treatment are required for other organ failure. 3. People who are known to be allergic to the test drug and its components; 4. People with inflammatory bowel disease, chronic diarrhea, malabsorption; 5. People with previous neuromuscular disease; 6. People with severe renal insufficiency (glomerular filtration rate <30 mL/min/1.73m2); 7. People with medical history of liver cirrhosis, active chronic hepatitis, or severe liver disease with serum GOT or GPT 3 times higher than the normal upper limit; 8. Patients who are taking colchicine or have a history of colchicine treatment (mainly chronic prescriptions for familial Mediterranean fever or gout); 9. People who have used immunosuppressants, corticosteroids, interleukin-1 inhibitors, or interleukin-6 inhibitors within 30 days before screening; 10. People who test positive for anti-SARS-CoV-2 immunoglobulin G (IgG); 11. People who have been vaccinated against COVID-19; 12. Any comorbidities that require surgery within 7 days before screening, or life-threatening comorbidities within 30 days before screening; 13. Suffering from malignant tumor diseases (excluding malignant tumors that have been cured and have not recurred in the past 5 years, completely resected basal cell and squamous cell skin cancers, and any type of cancer in situ that has been completely resected); 14. Suffering from any serious concomitant systemic disease, condition or disorder that the researcher believes should be prevented from participating in this study; 15. Pregnant or lactating women who have a positive human chorionic gonadotropin (hCG) test; 16. People who have a fertility plan or do not consent to effective non-drug contraception during the signing of the ICF to 6 months after the end of the trial; 17. Participated in other clinical studies within 30 days before screening; 18. People who have other factors that the researcher believes are not suitable for inclusion.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Colchicine Tablets
Colchicine Tablets (Each tablet contains colchicine 0.5mg)
Standard therapy
Standard therapy for COVID-19 according to the Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial 8th Edition)

Locations

Country Name City State
China Shanghai Public Health Clinical Center Shanghai Shanghai

Sponsors (2)

Lead Sponsor Collaborator
Shanghai Public Health Clinical Center Kunming Pharmaceuticals, Inc.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Recovery rate of clinical symptoms (fever, cough, expectoration, chest tightness, shortness of breath, dyspnea) and virus negative conversion rate (RT-PCR) at day 7 Day 7
Secondary Changes in the patients' clinical status through the WHO Clinical Progression Scale (scores 0-10) at day 7 The scale provides a measure of illness severity across a range from 0 (not infected) to 10 (dead) Day 7
Secondary Changes in the patients' clinical status through the WHO Clinical Progression Scale (scores 0-10) at day 10 The scale provides a measure of illness severity across a range from 0 (not infected) to 10 (dead) Day 10
Secondary Ventilator usage rate, usage time at day 7 Day 7
Secondary Ventilator usage rate, usage time at day 10 Day 10
Secondary Recovery rate and virus negative conversion rate (RT-PCR) of 10-day clinical symptoms (fever, cough, sputum expectoration, chest tightness, shortness of breath, dyspnea) Day 10
Secondary Time for the virus negative conversion (RT-PCR) Up to day 28
Secondary Time for observation in hospital Up to day 28
Secondary Length of hospital stay Up to day 28
Secondary Number of days in the intensive care unit Up to day 28
Secondary Changes in inflammatory markers at day 7: C-reactive protein Day 7
Secondary Changes in inflammatory markers at day 10: C-reactive protein Day 10
Secondary Changes in inflammatory markers at day 7: TNF-alfa Day 7
Secondary Changes in inflammatory markers at day 10: TNF-alfa Day 10
Secondary Changes in inflammatory markers at day 7: IL-6 Day 7
Secondary Changes in inflammatory markers at day 10: IL-6 Day 10
Secondary Changes in inflammatory markers at day 7: IL-1ß Day 7
Secondary Changes in inflammatory markers at day 10: IL-1ß Day 10
Secondary Changes in severity markers at day 7: D-dimer Day 7
Secondary Changes in severity markers at day 10: D-dimer Day 10
Secondary Changes in myocardial damage at day 7: hs-cTn Day 7
Secondary Changes in myocardial damage at day 10: hs-cTn Day 10
Secondary Changes in myocardial damage at day 7: NT-proBNP Day 7
Secondary Changes in myocardial damage at day 10: NT-proBNP Day 10
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection